A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Thorax

Volumn 70, Issue 4, 2015, Pages 359-367

  Pilkington, Gerlinde ^a   Boland, Angela ^a   Brown, Tamara ^b   Oyee, James ^c   Bagust, Adrian ^a   Dickson, Rumona ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Covance Clinical Development Services ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT;

ACNE; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COMPARATIVE STUDY; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; EDEMA; EMBASE; EVIDENCE BASED PRACTICE; FATIGUE; GRANULOCYTOPENIA; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; LOSS OF APPETITE; MEDLINE; META ANALYSIS (TOPIC); METASTASIS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PAIN; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING; WEAKNESS; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; LUNG NEOPLASMS; META ANALYSIS; SECONDARY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84925681278     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-205914     Document Type: Review

References (46)

1. Cancer Research UK. CancerStats: Lung Cancer and Smoking-Key Facts. http://info.cancerresearchuk.org/cancerstats/types/lung/
2. The Information Centre for Health and Social Care. National Lung Cancer Audit: Key findings about the quality of care for people with Lung Cancer in England and Wales. Report for the audit period 2006-2007. http://www.ic.nhs.uk/services/national-clinical-Audit-support-programme-ncasp/audit-reports/lung-cancer
3. National Institute for Health and Clinical Excellence. The diagnosis and treatment of lung cancer CG 121, 2011. https://www.nice.org.uk/guidance/cg121
4. Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
5. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
6. Brown T, Pilkington G, Bagust A, et al. Clinical and cost effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: A systematic review and economic evaluation. Health Technol Assess 2013; 17: 1-278.
7. Centre for Reviews and Dissemination. Centre for Reviews and Dissemination's guidance for undertaking reviews in health care, 2009. http://www.york.ac.uk/inst/crd/pdf/Systematic-Reviews.pdf
8. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025-34.
9. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-91.
10. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003; 21: 3016-24.
11. Smit EF, van Meerbeeck JPAM, Lianes P, et al. Three-Arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003; 21: 3909-17.
12. StataCorp. Stata Statistical Software: Release 9. College Station, TX: StataCorp LP, 2005.
13. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-Analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-34.
14. Williamson P, Smith C, Hutton J, et al. Aggregate data meta-Analysis with time-To-event outcomes. Stat Med 2002; 21: 3337-51.
15. Lunn DJ, Thomas A, Best N, et al. WinBUGS-A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput 2000; 10: 325-37.
16. Multi-parameter Evidence Synthesis Research Group. Formal methods for multiparameter evidence synthesis and their role in epidemiology and economic evaluation. http://www.bristol.ac.uk/cobm/research/mpes
17. Higgins J, Thompson S. Quantifying heterogeneity in a meta-Analysis. Stat Med 2002; 21: 1539-58.
18. Higgins J, Thompson S, Deeks J, et al. Measuring inconsistency in meta-Analyses. BMJ 2003; 327: 557-60.
19. Chen YM, Perng RP, Shih JF, et al. A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated. Br J Cancer 2004; 90: 359-65.
20. Douillard JY, Gervais R, Dabouis G, et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: Docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-Agent docetaxel or vinorelbine at progression: Final results of a randomised phase II study. Ann Oncol 2005; 16: 81-9.
21. Thomas P, Robinet G, Gouva S, et al. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer. GFPC 99-01 study (Groupe Francais de Pneumo-cancerologie). Lung Cancer 2006; 51: 105-14.
22. Chen YM, Perng RP, Shih JF, et al. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naive non-small-cell lung cancer in Taiwan. Lung Cancer 2007; 56: 363-9.
23. Langer CJ, Li S, Schiller J, et al. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007; 25: 418-23.
24. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-18.
25. Gebbia V, Galetta D, Caruso M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: A prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003; 39: 179-89.
26. Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005; 41: 81-92.
27. Helbekkmo N, Sundstrom SH, Aasebo U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97: 283-9.
28. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm cooperative study in Japan. Ann Oncol 2007; 18: 317-23.
29. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 3217-24.
30. Tan EH, Rolski J, Grodzki T, et al. Global lung oncology branch trial 3 (GLOB3): Final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009; 20: 1249-56.
31. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
32. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
33. Treat JA, Gonin R, Socinski MA, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 2010; 21: 540-7.
34. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
35. Chang J, Tsao T, Yang C, et al. A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer. Chang Gung Med J 2008; 31: 559-66.
36. Fukuoka M, Wu Y-L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-74.
37. Aaronson N, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
38. Bergman B, Aaronson N, Ahmedzai S. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 1994; 30a: 635-42.
39. Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 1996; 23(Suppl 5): 31-40.
40. Cella D, Bonomi A, Lloyd S, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199-220.
41. Ou S, Ziogas A, Zell J. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009; 4: 1083-93.
42. Rossell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-67.
43. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817.
44. Ardizzoni AL, Boni L, Tiseo M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-Analysis. J Natl Cancer Inst 2007; 99: 847-57.
45. Jiang J, Liang X, Zhou X, et al. A meta-Analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007; 57: 348-58.
46. Ferry D, Billingham L, Jarrett H, et al. British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine (1250 mg/m2) combined with cisplatin 50 mg/m2 (GC50) versus cisplatin 80 mg/m2 (GC80) versus carboplatin AUC 6 (GCb6) in advanced NSCLC. National Cancer Research Institute, 7th NCRI Cancer Conference. Liverpool, 2011.